GOVERNMENT OF INDIA
HEALTH AND FAMILY WELFARE
LOK SABHA

UNSTARRED QUESTION NO:3403
ANSWERED ON:29.07.2009
MOU FOR COLLABORATION RESEARCH AND CLINICAL STUDIES
Satpathy Shri Tathagata

Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether Central Council for Research in Ayurveda and Siddha (CCRAS) and Utkal University, Orissa have signed a Memorandum of Understanding (MoU) for undertaking collaboration, research and clinical studies;

(b) if so, the salient features of the said MoU; and

(c) the steps being taken by the Government to boost the traditional method of Ayurveda and Siddha?

Answer

MINISTER OF THE STATE IN THE MINISTRY OF HEALTH AND FAMILY WELFARE (SHRI GHULAM NABI AZAD)

(a) Yes.

(b) The salient features of the MoU are as follows:-

Joint Research and Development projects in the areas of Drug formulations, Efficacy of drugs, establishing diagnosis methods and other areas of basic medical and allied sciences are to be carried out with the financial assistance provided by the different funding agencies including Deptt. of AYUSH.

Recognition of CCRAS Hqrs. and Peripheral Institutions for Ph.D. with focused mandate in Drug Development (Pre-Clinical and Clinical) and Literature Research and providing facilities of these Centers to Ph.D. scholars enrolled at Utkal University.

Digitization of Ayurvedic manuscripts preserved at Parija Library of Utkal University by CCRAS and then joint publication as per AYUSH scheme.

Organizing and participating in Joint Symposia/ Conferences/ Workshops/ Short-term refresher courses conducted by both the organization.

Short-term and long term development programs on topics of mutual interest.

Medical and technical consultancy activities of mutual interest.

Exchange of faculty for guest lectures as well as for examiner-ships.

Extending Pre-clinical Toxicology and Pharmacokinetics/Clinical, Trial facilities/trials for bio-products developed by CCRAS and Utkal University and

Extending access to library and knowledge sharing facilities mutually for students and faculty in both the institutions.

(c) The steps taken by the Government to boost Ayurveda and Siddha are given in Annexure .

Annexure

The department is implementing number of Central and Centrally Sponsored Schemes for promotion of Ayurvedic and Siddha stream of medicines. Under these schemes, organization is provided to State Governments and Non- Government Organisations. Details of the scheme are given in the website of the department www.indianmedicine.nic.in and specific measures taken in this regard includes the following:-

(i) National Campaigns have been launched on the following themes for propagation & promotion of Ayurveda and Siddha :-
(a) Ksharsutra (A minimal invasive Ayurvedic Para Surgical Approach) for Ano-rectal Disorders:
(b) Geriatric care through Ayurveda & Siddha

(ii) Golden Triangle Partnership (GTP) Project:

Golden Triangle Partnership scheme is aimed to set up an integrated technology mission for scientific validation of classical/ classical based Ayurvedic products for the identified disease conditions for which the three apex organizations like Dept. of AYUSH/ CCRAS, CSIR and ICMR have joined hands for the above said purpose. The objectives of the scheme are:

1. To bring safe, effective and standardized ASHU (Ayurveda, Siddha, Homeopathy & Unani) products for the identified disease conditions

2. To develop new Ayurvedic/ Siddha/ Unani/ Homeopathic products effective in the disease conditions of national/ global importance. Products should be better than the available products in the market for such disease conditions

3. The criteria will be to have best quality, safe and effective products. Mechanism will be evolved to make products affordable for the domestic market

4. To utilize appropriate technologies for development of single and poly-herbal products to make it globally acceptable

5. To promote collaborative research on AYUSH with modern medicine/modern science institutions.

Under this scheme :-

(a) 38 formulations have been identified for 8 disease conditions out of which 20 formulations have been provided to CSIR for pre-clinical studies. The CSIR has submitted the status report of 10 formulations viz. 1. Tagradi Kwatha (Insomnia), 2. Medhya -6(ADHD), 3. Ashwagandha Churna (Anxiety neurosis), 4. Haritakyadi Churna(Dyslipidemia), 5. GTP-HN-1(Hypertension) , 6. Brahmi Ghrita (ADHD), 7. Gokshuradi guggulu(BPH), 8. Lakshadi Guggulu(Osteoporosis (Rasayana),9. Nirgundi tail (Amavatha -Joint Disorders), 10. Singhanada Guggulu(Amavatha -Joint Disorders)

(b) Drug development for Malaria 'Parijata Ghana Vati'. The work has been initiated at CSMDRIA&S, Chennai.

(c) The three batches of identified 8 Rasayogas have been prepared by Maharshi Ayurveda Pvt. Ltd. under the supervision of CCRAS and sent to IICT, Hyderabad along with detailed SOP's for standardization and Safety/ Toxicity studies. Chemical analysis, acute and sub-acute toxicity studies of all the three batches of 8 Rasayogas has been completed. Chronic toxicity studies (90 days) are under process.

(d) The inputs for the following protocols are drafted by CCRAS and provided to ICMR for further revision if any.
(i) Hypertension
(ii) Dyslipidemia
(iii) HIV/AIDS
(iv) Osteoporosis
(v) Rheumatoid Arthritis

(e) CCRAS has developed coded drug AYUSH QOL-2A for improvement in quality of life in HIV/AIDS patients. The standardization and preclinical studies have been completed and the drug profile has been handed over to ICMR for the initiation of clinical trials.

(f) The protocols for five diseases viz.

(i) Benign Prostate Hypertrophy, Osteoporosis, Hypertension, Dyslipidemia, HIV/AIDS have been designed by ICMR.

(iii) Extra Mural Research (EMR) Scheme:

Aims and Objectives:

1. To develop evidence based support on the efficacy of AYUSH drugs and therapies:

2. To generate data on safety, standardization and quality control for AYUSH products and practices;

3. To facilitate the validation of relevant and promising practices and skills of traditional health practioners and to further develop their utility for public benefit;

4. To retrieve and revive the rare classical literature and historical aspects of AYUSH;

5. To investigate the fundamental principles of Indian System of Medicine;

6. To generate a data bas e on various aspects of AYUSH practices;

7. To generate data on Heavy metals, Pesticide residues, microbial load, Safety / Toxicity etc. in the raw drugs & finished ASU & H drugs;

8. To utilize appropriate technologies for development of single and Poly-herbal / Herbo-mineral products to make it globally acceptable;

9. To develop the products those have IPR potentials to attract National/Multinational pharmaceutical companies.

10. Human Resources Development especially to inculcate Scientific aptitude and expertise relating to AYUSH systems.

There are 26 on-going projects under EMR on Ayurveda and Siddha.

IV Ayurvedic Pharmacopoeia Committee is working:-

To develop pharmacopoeial standards of single drugs & compound formulations.

To develop Standard Operating Procedures (SOP) or Method of Preparation (MOP);

To study the shelf life of the Ayurveda & Siddha drugs.

So far standards have been laid down for 540 single drugs and 101 compound formulations.